MARKET

GLMD

GLMD

Galmed Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.270
0.000
0.00%
Opening 11:20 04/23 EDT
OPEN
3.290
PREV CLOSE
3.270
HIGH
3.300
LOW
3.250
VOLUME
26.35K
TURNOVER
--
52 WEEK HIGH
6.29
52 WEEK LOW
2.960
MARKET CAP
82.02M
P/E (TTM)
-2.4231
1D
5D
1M
3M
1Y
5Y
Trends and Opportunities in Nonalcoholic Steatohepatitis (NASH) Market, Forecast To 2025
Apr 09, 2021 (Market Insight Reports) -- This research service provides a strategic analysis of the Stem Cell Banking Outsourcing Market 2021-2025. Learn how...
Market Insight Reports · 04/09 10:29
Non-Alcoholic SteatoHepatitis (NASH) Market Size to be Worth USD 54 Billion Growing at 58.6% CAGR till 2027; Industry Revenue, Statistics, Forecast by Reports And Data
Apr 05, 2021 (Market Insight Reports) -- The global non-alcoholic steatohepatitis (NASH) market was valued at USD 2.94 billion in 2019 and is projected to...
Market Insight Reports · 04/05 11:00
Nonalcoholic Steatohepatitis (NASH) Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Mar 24, 2021 (Market Insight Reports) -- The Global Nonalcoholic Steatohepatitis (NASH) Market is estimated to register a CAGR of over 52.9% during the...
Market Insight Reports · 03/24 12:00
Non-Alcoholic Steatohepatitis Market Size, Share, Trends, Growth Rate, By New Business Developments, Innovations, And Top Companies – Forecast 2021-2025 
Mar 24, 2021 (The Expresswire) -- Global "Non-Alcoholic Steatohepatitis Market" (2021-2025) research provides key analysis on the market status of the...
The Express Wire · 03/24 09:01
Acyl CoA Desaturase Market Insights, Trends, Size, Share, Outlook And Opportunity Analysis 2020-2027 by Ameco Research
pune, India, Wed, 24 Mar 2021 03:32:16 / Comserve Inc. / -- A new research report titled "Global Acyl CoA Desaturase Market" successfully exhibits the...
Comserve · 03/24 07:34
Non-Alcoholic Steatohepatitis Market Report 2020 by Key Players, Types, Applications, Forecast to 2026 || Merck, Galmed Pharmaceuticals Ltd., Cadila Healthcare Ltd., Gemphire Therapeutics Inc.
Mar 24, 2021 (Market Insight Reports) -- Global Non-Alcoholic Steatohepatitis Market Research Report 2020-2026 shares a versatile overview of the market...
Market Insight Reports · 03/24 05:59
Non-Alcoholic Steatohepatitis Market Size, Share, Global Industry Growth 2021, Pipeline Projects, Major Manufactures, Supply Demand Scenario, Project Economics and Survey till 2026
The Express Wire · 03/23 07:01
Non-Alcoholic Steatohepatitis Market Growth, Size, Analysis 2021, By Industry Share, Business Strategies, Emerging Demands, Growth Rate, Recent Trends, Opportunity, and Forecast to 2026
Mar 23, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The “Non-Alcoholic Steatohepatitis Market”...
The Express Wire · 03/23 05:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLMD. Analyze the recent business situations of Galmed Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GLMD stock price target is 16.40 with a high estimate of 25.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 7.43M
% Owned: 29.61%
Shares Outstanding: 25.08M
TypeInstitutionsShares
Increased
5
126.08K
New
5
107.72K
Decreased
5
259.24K
Sold Out
7
431.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.81%
Pharmaceuticals & Medical Research
+0.31%
Key Executives
President/Chief Executive Officer/Director
Allen Baharaff
Chief Financial Officer
Yohai Stenzler
Chief Operating Officer
Guy Nehemya
Chief Scientific Officer
Liat Hayardeny
Other
Tali Gorfine
Lead Director/Independent Director
David Sidransky
Director
Marshall Heinberg
Director
Ran Oren
Independent Director
Carol Brosgart
Independent Director
William Marth
Independent Director
Shmuel Nir
Independent Director
Tal Yaron-Eldar
Independent Director
Tali Yaron-Eldar
No Data
About GLMD
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Webull offers kinds of Galmed Pharmaceuticals Ltd stock information, including NASDAQ:GLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLMD stock methods without spending real money on the virtual paper trading platform.